Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naive (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms-MedSci.cn

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naive (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Wang, HF; Wei, XD; Jiang, Q; He, WJ; Li, QB; Liang, Y; Weng, JY; Chen, SN; Ma, HB; Chang, CK; Xu, YJ; He, Q; Chen, Z; Liu, LH; Men, LC; Cong, DH; Zhang, Z; Yang, DJ; Zhai, YF; Jie, J

BLOOD, 2023; 142 ():

科室
- - 订阅+
  - 更多科室
工具
服务